Metabolic Stability Assays
Predict Metabolic Clearance Before In Vivo Studies
Poor metabolic stability can lead to high clearance, short half-life, and inadequate drug exposure. Metabolic stability assays evaluate how quickly a compound is metabolized using in vitro systems such as liver microsomes, hepatocytes, and S9 fractions, generating data that support lead optimization, pharmacokinetic prediction, species selection, and candidate selection. At WuXi Biology and Testing, our integrated DMPK platform provides metabolic stability assessment across multiple species and therapeutic modalities to accelerate drug discovery and development.
In Vitro ADME Studies Annually
In Vivo Studies Annually
Successful IND Filings
Why Is Metabolic Stability Important?
Optimizing metabolic stability improves the likelihood that a drug candidate will achieve sufficient systemic exposure while maintaining an appropriate dosing profile. Understanding metabolic stability early in discovery helps identify compounds with appropriate pharmacokinetic properties before investing in expensive animal studies.
Metabolic stability studies can help researchers:
- Estimate intrinsic clearance
- Predict hepatic clearance
- Compare compound series during lead optimization
- Support IVIVE and PBPK modeling
- Select appropriate preclinical species
- Prioritize compounds for in vivo PK studies
- Investigate metabolism-related structure-activity relationships (SAR)
For many discovery programs, metabolic stability serves as one of the first ADME filters before in vivo pharmacokinetic evaluation.
Choose the Right In Vitro Metabolic Stability Model
No single in vitro model answers every metabolism question. Selecting the appropriate biological system depends on the stage of drug discovery, the metabolic pathways of interest, and the intended application of the data. Selecting the appropriate model improves data interpretation and supports more informed development decisions.
Liver Microsomes
Best for evaluating CYP-mediated Phase I metabolism.
Applications:
- Intrinsic clearance
- CYP-dependent metabolism
- Lead optimization
- Species comparison
Hepatocytes
Contain both Phase I and Phase II enzymes and transporters, providing a more physiologically relevant assessment of metabolism.
Applications:
- Overall metabolic stability
- Metabolite identification
- Hepatic clearance prediction
- Drug disposition studies
S9 Fractions
Include both microsomal and cytosolic enzymes.
Applications:
- Combined Phase I and Phase II metabolism
- Early metabolism screening
Intestinal Microsomes
Useful for compounds undergoing first-pass intestinal metabolism.
Applications:
- Oral drug development
- Intestinal CYP metabolism
- Gut wall clearance prediction
Additional systems, including liver cytosol, recombinant enzymes, and intestinal S9 fractions, are available when required to address specific metabolic questions.
Integrated Metabolic Stability Solutions Throughout Drug Discovery
Metabolic stability data become significantly more valuable when interpreted alongside other ADME assays.
Our integrated workflow combines metabolic stability with:
- Plasma protein binding
- CYP inhibition and induction
- Reaction phenotyping
- Metabolite identification
- Plasma stability
- Permeability assays
- PK studies
- PK/PD modeling
Together, these studies provide a comprehensive understanding of drug disposition and support more confident candidate selection.
Applications Across Drug Discovery
Metabolic stability assays support multiple stages of drug development.
Hit-to-Lead
- Rank compounds
- Eliminate rapidly metabolized molecules
Lead Optimization
- Improve exposure
- Understand SAR
- Guide medicinal chemistry
Candidate Selection
- Predict human clearance
- Compare species
- Support PBPK
IND-Enabling Studies
- Support PK interpretation
- Integrate with metabolite identification
- Inform regulatory studies
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Frequently Asked Questions
A metabolic stability assay measures how rapidly a drug candidate is metabolized by enzymes using in vitro biological systems such as liver microsomes or hepatocytes. The results help predict intrinsic clearance, half-life, and overall metabolic behavior before in vivo studies.
Liver microsomes primarily evaluate Phase I metabolism mediated by CYP enzymes. Hepatocytes contain intact cellular machinery, including Phase I and Phase II enzymes and transporters, providing a more comprehensive assessment of drug metabolism.
Intrinsic clearance (CLint) reflects the inherent ability of metabolic enzymes to eliminate a compound. It is widely used to estimate hepatic clearance, compare compound stability, and support IVIVE and PBPK modeling.
Metabolic stability provides valuable early insight into drug clearance and can support prediction of in vivo pharmacokinetics when combined with plasma protein binding, permeability, blood stability, and physiologically based modeling.
The optimal species depends on the intended preclinical model and development strategy. Human data are typically compared with commonly used laboratory species such as mouse, rat, dog, and monkey to identify potential species differences in metabolism.
Metabolic stability testing is commonly performed during hit-to-lead and lead optimization to prioritize compounds before animal studies. It is also used during candidate selection and IND-enabling development to support pharmacokinetic interpretation.
Metabolic stability is often integrated with plasma protein binding, CYP inhibition, CYP induction, plasma stability, permeability, metabolite identification, reaction phenotyping, and in vivo pharmacokinetic studies to provide a more complete understanding of drug disposition.



